Board of Directors
Prior to joining Selecta Biosciences in 2010, Dr. Cautreels was Chief Executive Officer of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group, in Brussels, Belgium, from 2005 until Solvay Pharmaceuticals was acquired by Abbott Laboratories in February 2010.
Before becoming the CEO of Solvay Pharmaceuticals, Dr. Cautreels was its Global Head of R&D from 1998. Prior to joining Solvay, he was employed by Sanofi, Sterling‑Winthrop from 1979 to 1994, and Nycomed‑Amersham from 1994 to 1998 in a variety of R&D management positions in Europe and in the United States. Dr. Cautreels is a director of Galapagos NV in Mechelen, Belgium. He held director positions at Seres Therapeutics, Inc. in Cambridge Massachusetts from January 2013 to July 2016, at Innogenetics NV in Gent, Belgium and at ArQule Inc. in Woburn, Massachusetts each from 1999 to 2006. He was the President of the Belgian‑Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. Dr. Cautreels received his Ph.D. in Chemistry, specializing in Mass Spectrometry, from the University of Antwerp (Antwerp, Belgium), and his financial and business training from the Advanced Management Program at Harvard Business School.
Mr. Barabe has been a director of Selecta Biosciences since July 2016. He also is a member of the Boards of Directors of Veeva, a life sciences service company, since September 2015, Vigilant Biosciences, a private medical device company, since November 2014, Opexa Therapeutics, a biotechnology company, since March 2014, and ArQule, a biotechnology company, since November 2001.
Mr. Barabe also serves on the Board and Executive Committee of Project Open Hand, a San Francisco-based nonprofit providing meals to the elderly and ill. Mr. Barabe retired in June 2013 from his position as Executive Vice President and Chief Financial Officer of Affymetrix, Inc. Previously, from July 2006 until March 2010, he was Senior Vice President and Chief Financial Officer of Human Genome Sciences, Inc. He was with Regent Medical Limited, a U.K.-based, privately owned, surgical supply company, where he was Chief Financial Officer, from 2004 to 2006. Mr. Barabe served with Novartis AG from 1982 through August 2004 in a succession of senior executive positions in finance and general management, most recently as the Chief Financial Officer of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis. Mr. Barabe received his B.B.A. degree from the University of Massachusetts (Amherst) and his M.B.A. degree from the University of Chicago.
Dr. Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a Physician‑Scientist in the Department of Anesthesiology at Brigham and Women’s Hospital (BWH), positions he has held since 2004. Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH.
Prior to joining the HMS faculty, Dr. Farokhzad completed his postgraduate clinical and postdoctoral research trainings, respectively, at BWH/HMS and Massachusetts Institue of Technology (MIT) in the laboratory of Dr. Langer. He is the recipient of the 2013 RUSNANOPRIZE. Dr. Farokhzad has been directly involved in the launch and development of four biotechnology companies and, on occasion, has assumed additional roles in support of management. From 2006 to 2014, Dr. Farokhzad served on the Board of Directors of BIND Therapeutics, Inc. He received his M.D. and M.A. from Boston University School of Medicine and his M.B.A. from MIT.
Mr. Hutt is a Senior Counsel in the Washington, D.C., law firm of Covington & Burling, specializing in food and drug law. Mr. Hutt began his law practice with the firm in 1960, and, except for his four years in the government, has continued at the firm ever since. Mr. Hutt served as Chief Counsel for the FDA during 1971 to 1975.
Since 1994, he has taught a course on Food and Drug Law at Harvard Law School. Mr. Hutt serves on the board of directors of Seres Therapeutics, Inc., Xoma Corp., BIND Therapeutics, Inc., Concert Pharmaceuticals, Inc., Flex Pharma, Inc. and Q Therapeutics, Inc. From 2009 to 2015, Mr. Hutt served on the Board of Directors of DBV Technologies; from 2001 to 2014, he served on the Board of Momenta Pharmaceuticals, Inc.; from 2008 to 2011, he served on the Board of Celera Corp.; and from 2002 to 2012, he served on the Board of ISTA Pharmaceuticals, Inc. Mr. Hutt received his B.A. from Yale University, his LL.B. from Harvard Law School and his L.L.M. from New York University.
Dr. Nashat has been a Managing General Partner at Polaris Venture Partners, a venture capital firm, since 2009, and focuses on investments in the life sciences. He currently serves on the board of directors of Fate Therapeutics, Inc., aTyr Pharma, Inc. and several private companies. Dr. Nashat has also served as a director of Receptos, Inc., Adnexus Therapeutics, Inc. (acquired by Bristol‑Myers Squibb Company) and other private companies.
Dr. Nashat completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Langer. Dr. Nashat earned both his M.S. and B.S. in Materials Science and Mechanical Engineering at the University of California, Berkeley.
Mr. Sallin has served as the Chief Executive Officer of NanoDimension, a venture capital firm, since 2002, and is the founder of that firm. Since 2014, Mr. Sallin has served as a Strategic Advisory Board member of the École Polytechnique Fédérale de Lausanne (EPFL). Since 2002, Mr. Sallin has worked to promote nanotechnology around the world, and has received the NSTI Fellow Award and 2012 EPFL Alumni Award for his contribution to the field of nanotechnology.
Mr. Sallin has worked to generate and close investments of hundreds of millions of dollars into several of NanoDimension’s portfolio companies. He currently serves as a board member of View, Inc., CROCUS Technology and Tarveda Therapeutics, Inc. Mr. Sallin received his Masters in Physical Engineering from EPFL in Lausanne, Switzerland.
Dr. Springer is Latham Family Professor of Biological Chemistry and Molecular Pharmacology and Professor of Medicine at Harvard Medical School and Children’s Hospital Boston. He founded LeukoSite in 1993, which developed three drugs approved by the FDA. He has served as Resident Professor at Pfizer. He has invested in Selecta since the B round and is a founding investor in Moderna and Editas Medicine. He is a founder, investor, and board member of Scholar Rock and Morphic Therapeutic.
Dr. Springer is a member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer discovered many of the adhesion molecules of the immune and circulatory systems and the three-step paradigm for leukocyte emigration from the bloodstream by which white blood cells patrol the body to detect infection and accumulate to fight disease. He received his B.A. in Biochemistry from the University of California and his Ph.D. from Harvard University.
Mr. Zenner was elected to the Board of Directors of Selecta Biosciences in June 2017. He served as President and Chief Executive Officer of Hoffmann-La Roche Inc., North America – the prescription drug unit of Roche Group, a leading research-based healthcare enterprise – from 1993 to 2001.
Prior to his retirement, Mr. Zenner held various positions during his 32-year career at Roche, since joining the company as a sales representative in 1969. He currently serves as Chairman of the Board and a director of both ArQule, Inc. and West Pharmaceutical Services, Inc. Previously, Mr. Zenner served as a director of Par Pharmaceuticals and several other public and private companies. He received his B.S.B.A. from Creighton University and his M.B.A. from Fairleigh Dickinson University.